---
layout: default
title: Platinum
parent: 僅模型預測 (L5)
nav_order: 1053
evidence_level: L5
indication_count: 10
---

# Platinum
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Platinum (DB12257): From Undefined Indication to Urinary Bladder Carcinoma

> ⚠️ **Data Quality Notice**: DrugBank entry DB12257 is registered simply as **"Platinum"** — a generic/elemental entry, not a specific prescribable compound (e.g., cisplatin, carboplatin, oxaliplatin each have their own DrugBank IDs). `original_moa`, `original_indications`, and Taiwan market status are all empty or unmarketed. All clinical and literature evidence below was retrieved under this generic label and reflects **platinum-based chemotherapy in general**, not a verified pharmacological profile of this specific entity. This caveat should be resolved before any downstream decision is finalized.

## One-Sentence Summary

Platinum (DB12257) has no recorded original indication or mechanism of action in the source data.
The TxGNN model predicts activity against **Urinary Bladder Carcinoma**, with **50 clinical trials** and **20 publications** retrieved as supporting evidence — however, this evidence largely reflects the already-established role of platinum-based chemotherapy (e.g., cisplatin/gemcitabine regimens) as standard of care in bladder cancer, rather than a genuinely novel repurposing signal.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not recorded (drug entry has no listed original indications) |
| Predicted New Indication | Urinary Bladder Carcinoma |
| TxGNN Prediction Score | 99.34% |
| Evidence Level | L1 |
| US/Taiwan Market Status | Not Marketed (0 licenses) |
| Number of NDAs | 0 |
| Recommended Decision (algorithmic) | Proceed with Guardrails |

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available for DB12257 (`original_moa` = data gap). Based on the naming convention and the retrieved evidence, this entry most likely functions as an upper-level/generic label for platinum-class chemotherapy agents, whose established mechanism is DNA cross-linking leading to apoptosis of rapidly dividing cells.

Notably, **all top 10 TxGNN predictions for this drug are bladder cancer subtypes** (urinary bladder carcinoma, infiltrating bladder urothelial carcinoma, non-invasive bladder urothelial carcinoma, urachal/signet-ring/colonic-type/colloid/mixed/clear-cell adenocarcinoma variants, and urinary bladder neoplasm). This pattern strongly suggests the model is detecting an already well-known clinical association — platinum-based chemotherapy (cisplatin + gemcitabine) is the existing standard-of-care first-line and neoadjuvant/adjuvant regimen for muscle-invasive and metastatic urothelial carcinoma (NCCN/EAU/ESMO guidelines). This is therefore best interpreted as **confirmation of established practice** rather than a novel repurposing hypothesis, pending clarification of what specific compound DB12257 represents.

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT04700124](https://clinicaltrials.gov/study/NCT04700124) | Phase 3 | Completed | 808 | KEYNOTE-B15/EV-304: perioperative enfortumab vedotin + pembrolizumab vs. standard neoadjuvant gemcitabine/cisplatin in cisplatin-eligible MIBC |
| [NCT00028756](https://clinicaltrials.gov/study/NCT00028756) | Phase 3 | Completed | 285 | Immediate vs. deferred adjuvant chemotherapy after radical cystectomy for pT3-pT4/N+ bladder TCC |
| [NCT01993979](https://clinicaltrials.gov/study/NCT01993979) | Phase 3 | Unknown | 261 | Perioperative platinum-based chemotherapy vs. surveillance in upper tract urothelial cancer (POUT-type design) |
| [NCT01089088](https://clinicaltrials.gov/study/NCT01089088) | Phase 2 | Completed | 63 | Cisplatin + gemcitabine + sunitinib as first-line therapy for advanced urothelial carcinoma |
| [NCT00055601](https://clinicaltrials.gov/study/NCT00055601) | Phase 2 | Completed | 97 | Paclitaxel/cisplatin vs. 5-FU/cisplatin with bladder preservation for muscle-invading bladder cancer |
| [NCT00003930](https://clinicaltrials.gov/study/NCT00003930) | Phase 1/2 | Completed | 84 | Transurethral surgery + taxol/cisplatin + irradiation for stage II-III bladder cancer |
| [NCT00714948](https://clinicaltrials.gov/study/NCT00714948) | Phase 2 | Terminated | 2 | Gemcitabine + split-dose cisplatin + sorafenib in chemo-naïve advanced urothelial carcinoma |
| [NCT02631590](https://clinicaltrials.gov/study/NCT02631590) | Phase 2 | Completed | 24 | Copanlisib + gemcitabine + cisplatin in advanced urothelial/cholangiocarcinoma |
| [NCT00777491](https://clinicaltrials.gov/study/NCT00777491) | Phase 2 | Completed | 70 | Comparison of chemoradiation regimens (5-FU/cisplatin vs. gemcitabine) for muscle-invasive bladder cancer |
| [NCT01326871](https://clinicaltrials.gov/study/NCT01326871) | Phase 1/2 | Completed | 68 | ALT-801 + cisplatin + gemcitabine in muscle-invasive/metastatic urothelial cancer |

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [32145825](https://pubmed.ncbi.nlm.nih.gov/32145825/) | 2020 | RCT (Phase 3) | Lancet | POUT trial: adjuvant platinum-based chemotherapy improves outcomes in upper tract urothelial carcinoma after nephroureterectomy |
| [36967359](https://pubmed.ncbi.nlm.nih.gov/36967359/) | 2023 | Review | European Urology | EAU guidelines update on upper urinary tract urothelial carcinoma |
| [38702396](https://pubmed.ncbi.nlm.nih.gov/38702396/) | 2024 | Review | Nature Reviews Urology | Evolving treatment landscape of metastatic urothelial cancer; cisplatin-based chemotherapy remains first-line SOC |
| [34861372](https://pubmed.ncbi.nlm.nih.gov/34861372/) | 2022 | Review (Guideline) | Annals of Oncology | ESMO Clinical Practice Guideline for bladder cancer diagnosis, treatment and follow-up |
| [40478748](https://pubmed.ncbi.nlm.nih.gov/40478748/) | 2025 | Review | CA: A Cancer Journal for Clinicians | Perioperative considerations in urothelial carcinoma management |
| [37071838](https://pubmed.ncbi.nlm.nih.gov/37071838/) | 2023 | Trial Update (Phase 3) | J Clin Oncol | JAVELIN Bladder 100: avelumab first-line maintenance after platinum chemotherapy |
| [39536751](https://pubmed.ncbi.nlm.nih.gov/39536751/) | 2024 | Cohort/Trial | Cell Reports Medicine | PD-1 blockade + platinum chemotherapy in small cell/neuroendocrine bladder and prostate cancers |
| [38244927](https://pubmed.ncbi.nlm.nih.gov/38244927/) | 2024 | Phase 2 Trial | Annals of Oncology | TROPHY-U-01: sacituzumab govitecan in mUC progressing after platinum chemotherapy and checkpoint inhibitors |
| [40782344](https://pubmed.ncbi.nlm.nih.gov/40782344/) | 2025 | Review | Cancer | Top clinical advances in bladder cancer, including new perioperative and first-line standards |
| [28982752](https://pubmed.ncbi.nlm.nih.gov/28982752/) | 2017 | Review | JNCCN | Urothelial carcinoma of the bladder and the rise of immunotherapy following platinum-based chemotherapy failure |

## Cytotoxicity

*Included because the predicted indication is oncologic and the evidence base is dominated by platinum-based cytotoxic chemotherapy regimens; however, the exact compound identity behind DB12257 remains unconfirmed.*

| Item | Content |
|------|------|
| Cytotoxicity Classification | Conventional cytotoxic — platinum-class agent (representative of cisplatin/carboplatin/oxaliplatin family; specific compound unconfirmed) |
| Myelosuppression Risk | Moderate–High; typical of platinum agents (carboplatin generally more myelosuppressive than cisplatin) |
| Emetogenicity Classification | High (platinum agents, particularly cisplatin, are classified as highly emetogenic) |
| Monitoring Items | CBC with differential, renal function (creatinine clearance), electrolytes (Mg, K, Ca), audiometry, peripheral neuropathy assessment |
| Handling Protection | Yes — must follow cytotoxic/hazardous drug handling regulations |

## Safety Considerations

Please refer to the package insert for safety information. No key warnings, contraindications, or drug interaction data are currently available for this entry (TFDA label data collection is a blocking gap — see Next Steps).

## Conclusion and Next Steps

**Decision: Hold (Data Quality Review Required)**

**Rationale:**
Although the aggregated evidence reaches L1 strength and the algorithmic scoring suggests "Proceed with Guardrails," this evidence is proxy evidence for platinum-based chemotherapy as a drug class — already the established standard of care in bladder cancer — rather than a confirmed profile of the specific DB12257 "Platinum" entity. A blocking data gap (TFDA warnings/contraindications, DG001) also prevents any safety pre-screening. Proceeding on repurposing logic without first resolving the entity's identity risks producing a report that misrepresents an already-standard therapy as a novel finding.

**To proceed, the following is needed:**
- Clarify which specific platinum compound (cisplatin, carboplatin, oxaliplatin, or true elemental platinum) DB12257 is intended to represent
- Obtain TFDA package insert data to resolve DG001 (blocking) before any S1 safety screening
- Obtain mechanism of action data via DrugBank API to resolve DG002
- If DB12257 is confirmed to correspond to a platinum compound already indicated for bladder cancer, reclassify this as "existing standard of care" rather than a repurposing candidate
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

